World Clinical Trials Market Report 2022: A Decline of 6% in 2020 Due to COVID-19 but a Market Valued at $78.3 Billion by 2030
28 juin 2022 04h28 HE
|
Research and Markets
Dublin, June 28, 2022 (GLOBE NEWSWIRE) -- The "Clinical Trials Market Size, Share & Trends Analysis Report by Phase (Phase I, Phase II, Phase III, Phase IV), by Study Design, by Indication (Pain...
Global eClinical Solutions Market Report 2022-2026: Decentralized Clinical Trials, Rising Mobile Health Adoption, and Cloud-based Platforms Lower Costs and Enhance Efficiency
29 avr. 2022 05h18 HE
|
Research and Markets
Dublin, April 29, 2022 (GLOBE NEWSWIRE) -- The "Global eClinical Solutions Growth Opportunities" report has been added to ResearchAndMarkets.com's offering. eClinical solutions are the backbone for...
Phathom Pharmaceuticals Announces Positive Topline Results from PHALCON-EE Pivotal Phase 3 Erosive Esophagitis Trial
18 oct. 2021 07h00 HE
|
Phathom Pharmaceuticals
Vonoprazan met its primary non-inferiority endpoints in both healing and maintenance phasesVonoprazan demonstrated superior healing rates in patients with moderate-to-severe disease at Week 2 versus...
Novavax Completes Enrollment of PREVENT-19, COVID-19 Vaccine Pivotal Phase 3 Trial in the United States and Mexico
22 févr. 2021 07h00 HE
|
Novavax, Inc.
PREVENT-19 enrolls 30,000 volunteers across 118 sites in the U.S. and Mexico GAITHERSBURG, Md., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing...
Phathom Pharmaceuticals Announces Completion of Patient Enrollment in Pivotal Phase 3 Helicobacter pylori (H. pylori) Trial
19 janv. 2021 08h30 HE
|
Phathom Pharmaceuticals
Topline results expected in second quarter of 2021NDA submission for H. pylori expected in second half of 2021 FLORHAM PARK, N.J., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals,...
Vir Biotechnology and GSK announce global expansion to Phase 3 of COMET-ICE study evaluating VIR-7831 for the treatment of COVID-19
06 oct. 2020 08h18 HE
|
Vir Biotechnology, Inc.
Independent Data Monitoring Committee recommended on September 30, 2020 that the study continue into Phase 3 based on a positive evaluation of safety and tolerability data from the Phase 2...
ObsEva Progressing Toward U.S. Phase 3 Trial for Nolasiban in IVF Following Recent FDA Meeting
19 juin 2019 01h00 HE
|
ObsEva SA
Geneva, Switzerland and Boston, MA – June 19, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel...
Entasis Therapeutics Initiates Global Phase 3 Pivotal Trial of ETX2514SUL for Patients with Carbapenem-Resistant Acinetobacter Infections
04 avr. 2019 08h00 HE
|
Entasis Therapeutics Holdings Inc.
WALTHAM, Mass., April 04, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company developing novel antibacterials to treat serious...
Adamas Announces First Patient Enrolled in Phase 3 Trial of ADS-5102 in Multiple Sclerosis Patients with Walking Impairment
03 avr. 2018 09h00 HE
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., April 03, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the first patient has been enrolled in its pivotal Phase 3 clinical trial of...
Innovate Biopharmaceuticals to present progress towards phase 3 celiac disease trials at BIO 2017 Convention
06 juin 2017 08h07 HE
|
Innovate Biopharmaceuticals, Inc
RALEIGH, N.C., June 06, 2017 (GLOBE NEWSWIRE) -- Innovate Biopharmaceuticals, a leader in developing innovative therapies for autoimmune and inflammatory diseases, will present on its phase 3 drug...